Translational Pathways for Cardiovascular Devices – Session IV: Methods for Coronary Stent Development – Chuck Simonton Practice Quiz – ISCTR | International Society for Cardiovascular Translational Research

Quiz Summary

0 of 6 Questions completed

Questions:

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You must first complete the following:

Results

Quiz complete. Results are being recorded.

Results

You have completed the practice quiz, please continue on to the next session.

Current
Review
Answered
Correct
Incorrect

Question 1 of 6

1. Question
Which of the following is the mechanism of Everolimus on reducing cell proliferation?
- Everolimus binds to FKBP12 and inhibits mTOR
- Everolimus binds to FKBP12 and increases protein synthesis
- Everolimus binds directly to mTOR and increases protein synthesis
- Everolimus interacts with the growth factor receptor and reduces protein synthesis
Correct

Incorrect
Question 2 of 6

2. Question
Pharmacokinetics and degradation profile of a drug-eluting stent should guide the selection of time points for efficacy assessment in the animal model?
- True
- False
Correct

Incorrect
Question 3 of 6

3. Question
Which of the following recommended evaluation time points for drug-eluting stents in the animal is correct?
- Acute 3, 7, 30 days
- Sub-Chronic 28, 60, 90 days
- Chronic: 1, 2 years
- Chronic 3 years
Correct

Incorrect
Question 4 of 6

4. Question
Drug eluting stents in the US are regulated by and classified as:
- CDRH and considered a Class l device
- CDRH and considered a Class II device
- CDRH and considered a Class III device
- CEBER and considered a Class II device
Correct

Incorrect
Question 5 of 6

5. Question
Regulatory classification of drug-eluting stents are?
- Class II in the US and Class II in Europe
- Class III in the US and Class II in Europe
- Class II in the US and Class III in Europe
- Class III in the US and Class III in Europe
Correct

Incorrect
Question 6 of 6

6. Question
Long term outcomes of stenting include which of the following?
- In-stent restenosis occurs at the rate of 2.5% per year, of which 25% present with STEMI
- In-stent restenosis occurs at the rate of 2.5% per year, of which 50% present with STEMI
- In-stent restenosis occurs at the rate of 5% per year, of which 50% present with STEMI
- In-stent restenosis occurs at the rate of 7% per year, of which 40% present with STEMI
Correct

Incorrect

Quiz Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question

4. Question

5. Question

6. Question